MECP2

Across TCGA pan-cancer cohorts, MECP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MECP2 data layer compared with 24 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MECP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MECP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where MECP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.594	0.168	.001	31	view →
CCRCC	OS	Median	All	1.000	0.663	.010	20	view →
LSCC	DFS	Tertile	II,III,IV	0.528	0.904	.005	15	view →
LUAD	DFS	Tertile	III,IV	0.562	0.979	.003	15	view →
HNSC	DFS	Median	All	0.713	0.837	.042	1	view →
GBM	OS	Median	All	0.855	0.679	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MECP2–PDAC (DFS)

Open the PDAC breakdown →